Associated Papers
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.
Vasudev NS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
36815791 (PubMed )
Supplement: ccr-22-1936_supplementary_table_s2_suppts2.xlsx › Sheet1
PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma.
He X et al.
Clinical and Translational Medicine, 2022
36178086 (PubMed )
Supplement: CTM2-12-e1062-s007.xlsx › Sheet1
Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft.
Passeri T et al.
Cancers, 2022
Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.
Boot A et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
35058360 (PubMed )
Supplement: pnas.2114024119.sd08.xlsx › Dataset.S8
Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort.
Zhan Q et al.
Ebiomedicine, 2021
34839264 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Distinct genomic profile in h. pylori-associated gastric cancer.
Zhang X et al.
Cancer Medicine, 2021
33751865 (PubMed )
Supplement: CAM4-10-2461-s001.xlsx › somatic_muts.gastric_samples.le
Select a paper to view details